|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Predictive biomarkers in precision medicine and drug development against lung cancer显示文摘The molecular characterization of various cancers has shown that cancers with the same origins,histopathologic diagnoses,and clinical stages can be highly heterogeneous in their genetic and epigenetic alterations that cause tumorigenesis.A number of cancer driver genes with functional abnormalities that trigger malignant transformation and that are required for the survival of cancer cells have been identified.Therapeutic agents targeting some of these cancer drivers have been successfully developed,resulting in substantial improvements in clinical symptom amelioration and outcomes in a subset of cancer patients.However,because such therapeutic drugs often benefit only a limited number of patients,the successes of clinical development and applications rely on the ability to identify those patients who are sensitive to the targeted therapies.Thus,biomarkers that can predict treatment responses are critical for the success of precision therapy for cancer patients and of anticancer drug development.This review discusses the molecular heterogeneity of lung cancer pathogenesis;predictive biomarkers for precision medicine in lung cancer therapy with drugs targeting epidermal growth factor receptor(EGFR),anaplastic lymphoma kinase(ALK),c-ros oncogene 1 receptor tyrosine kinase[ROSl),and immune checkpoints;biomarkers associated with resistance to these therapeutics;and approaches to identify predictive biomarkers in anticancer drug development.The identification of predictive biomarkers during anticancer drug development is expected to greatly facilitate such development because it will increase the chance of success or reduce the attrition rate.Additionally,such identification will accelerate the drug approval process by providing effective patient stratification strategies in clinical trials to reduce the sample size required to demonstrate clinical benefits. | Bingliang Fang Reza J Mehran John V Heymach Stephen G Swisher | 2015 | Chinese Journal of Cancer2015，34，7： | 5 |
| 2 | Induction of p53 regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (NGN 201) and radiation therapy显示文摘 | SWISHER S G ROTHJ A KAMAKI R | 2003 | Clin Cancer Res2003，9，1： | 1 |
| 3 | Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer显示文摘 | Nemunaitis J Swisher S G Timmons T | 2000 | J Clin Oncol2000，18，3： | 1 |
| 4 | Treatment outcomes ofresected esophageal cancer显示文摘 | Hofstetter W Swisher S G Correa A M | 2002 | Ann Surg2002，236，3： | 1 |
| 5 | Long-term outcome of phase Ⅱtrial evaluating chemotherapy,chemoradiotherapy,and surgery for locoregionally advanced esophageal cancer显示文摘 | Swisher S G Ajani J A Komaki R | 2003 | Int J Radiat Oncol Biol Phys2003，57，1： | 1 |
| 6 | Phase Ⅱ study of a paclitaxel-based chemoradiation regimen with selective surgical sal- vage for resectable locoregionally advanced esophageal cancer: ini- tial reporting of RTOG 0246 显示文摘 | Swisher S G Winter K A Komaki R U | 2012 | lnt J Radiat Oncol Biol Phys2012，82，5： | 1 |
| 7 | Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy显示文摘 | Bruzzi J F Swisher S G Truong M T | 2007 | Cancer2007，109，1： | 1 |
| 8 | Clinical update of Ad-P53 gene therapy for lung cancer显示文摘 | Swisher S G Roth J A | 2002 | Surg Oncol Clin N Am2002，11，3： | 1 |
| 9 | Fluorescein diacetate hydrolysis as an estimator of microbial biomass on coniferous needle surfaces 显示文摘 | Swisher R Carroll G C | 1980 | Microbial Ecology1980，6，3： | 1 |
| 10 | Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy显示文摘 | Swisher S G Roth J A Komaki R | 2003 | Clin Cancer Res2003，9，1： | 1 |
| 11 | Clinical update of Ad-p53 gene therapy for lung cancer显示文摘 | Swisher S G Roth J A | 2002 | Surg Oncol Clin N Am2002，11，3： | 1 |
| 12 | Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines显示文摘 | GU J SWISHER S G | 2000 | Cancer Res2000，60，5： | 1 |
| 13 | Clinical update of Ad-p53 gene therapy for lung cancer显示文摘 | Swishers G Rothj A | 2002 | J Am Surg Oncol Clin2002，11，30： | 1 |
| 14 | Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter显示文摘 | Putnam J B Walsh G L Swisher S G | 2000 | Ann Thorac Surg2000，69，2： | 1 |
| 15 | Clinical update of AdE-p53 gene therapy for lung cancer显示文摘 | Swisher S G Roth J A | 2002 | Surg Oncol Clin N Am2002，11，3： | 1 |
| 16 | Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 ( INGN 201 ) and radiation therapy 显示文摘 | Stephen G Swisher B Jack A | 2003 | Clinical Cancer Research2003，9，1： | 1 |
| 17 | Antitumor effect of adenovirus-mediated Bax gene transfer on p53-sensitive and p53-resistant cancer lines 显示文摘 | KAGAWA J SWISHER S G FANG B et at | 2000 | Cancer Res2000，60，5： | 1 |
| 18 | Gender-based analysis of esophageal cancer patients undergoing preoperative chemoradiation: differences in presentation and therapy outcome 显示文摘 | Rohatgi P R Correa A M Swisher S G | 2006 | Dis Esophagus2006，19，3： | 1 |
| 19 | Outpatient management of malignant phural effusion by a chronic indwelling pleural eatheter 显示文摘 | Putnam J B Walsh G L Swisher S G | 2000 | Ann Thorac Surg2000，69，2： | 1 |
| 20 | Topotecan in platinum-and paclitaxel-resistant ovarian cancer显示文摘 | SWISHER E M MUTCH D G RADER J S | 1997 | Gynecol Oncol1997，66，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员